Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Busting a myth: Is achieving US drug prices in Europe impossible?
To answer this question, the authors searched for evidence in the individual countries. Germany and the UK, for example, are the two European countries where...